日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer

一项比较吉西他滨联合顺铂(GP)与吉西他滨联合卡铂(GC)作为转移性三阴性乳腺癌患者一线治疗方案的II期随机试验

Gong, C; Zhao, Y; Wang, L; Cao, J; Tao, Z; Li, T; Zhao, M; Miao, H; Hu, X; Wang, B

Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database

利用美国二级数据库,制定和评估早期三阴性乳腺癌患者真实世界临床终点的定义

Hu, X; Earla, J R; Cruz, G I; Mohammed, H; Privette, T; Hernandez, A; Krishnan, R; Pan, W; Haiderali, A

[Impact of conditioning intensity on transplant outcomes following allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic neoplasms: a multicenter retrospective cohort study]

[预处理强度对骨髓增生异常综合征患者异基因造血干细胞移植后移植结果的影响:一项多中心回顾性队列研究]

Wang, L; Zhang, Z L; Zhang, R X; Chen, H R; Hu, M L; Zhao, Y M; Shi, W; Cao, Y; Hu, X X

[Efficacy and safety of venetoclax-cytarabine-homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation in refractory/relapsed acute myeloid leukemia with RUNX1::RUNX1T1: a retrospective study]

[基于维奈托克-阿糖胞苷-高三尖杉酯碱的细胞减灭疗法在异基因造血干细胞移植治疗难治性/复发性 RUNX1::RUNX1T1 急性髓系白血病中的疗效和安全性:一项回顾性研究]

Zhang, Z L; Jin, C W; Li, S; Wang, L X; Huang, J Y; Jiang, C H; Lu, H Y; Hu, X X

A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer

一项针对HR阳性/HER2阴性晚期乳腺癌患者的tibremciclib单药治疗及联合氟维司群治疗的I期剂量递增和剂量扩展研究

Zhang, J; Liu, R; Gao, S; Chen, W; Han, X; Wang, Z; Zhou, H; Wang, Y; Chen, J; Ma, Y; Liu, K; Shen, Z; Ding, L; Li, P; Hu, X

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

曲妥珠单抗德鲁替康治疗激素受体阳性、HER2低表达或HER2超低表达转移性乳腺癌的患者报告结局:来自随机DESTINY-Breast06试验的结果

Hu, X; Curigliano, G; Yonemori, K; Bardia, A; Barrios, C H; Sohn, J; Lévy, C; Jacot, W; Tsurutani, J; Roborel de Climens, A; Wu, X; Andrzejuk-Ćwik, A; Mbanya, Z; Dent, R

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06

在DESTINY-Breast06研究中,对PATHWAY HER2 (4B5)检测方法进行分析和临床验证,以评估HER2低表达/HER2超低表达状态以及患者是否适合接受曲妥珠单抗德鲁替康治疗。

Shami, R; Salgado, R; Bardia, A; Curigliano, G; Hu, X; Dent, R; Pierga, J-Y; Tsurutani, J; Wildiers, H; Ricciardi, G; Marchiò, C; Penault-Llorca, F; Bor-Angelier, C; Manoogian, M; Lucas, S; Olson, M T; Liu, X; Toro, P; Baker, A F; Fang, Q; Su, J; Yoder, A; Andrzejuk-Ćwik, A; Darilay, A; Matsuo, T; Jones, F; Viale, G

The innate immune receptor NLRX1 is a novel required modulator for mPTP opening: implications for cardioprotection.

先天免疫受体 NLRX1 是 mPTP 开放的新型必需调节因子:对心脏保护的意义

Xiao Y, Hu X, Rudolphi C F, Nollet E E, Nederlof R, Wang Q, Bakker D, Nikolaou Panagiota Efstathia, Knol J C, Haas R R Goeij-de, Henneman A A, Pham T V, Jimenez C R, Grootemaat A E, van der Wel N N, Girardin S E, Kaludercic N, van der Velden J, Onódi Z, Leszek P, Varga Z V, Ferdinandy P, Preckel B, Weber N C, Hollmann M W, Di Lisa F, Zuurbier C J

The scaling relationship between leaf nitrogen and phosphorus concentrations in vascular epiphytes

维管附生植物叶片氮磷浓度之间的标度关系

Hu, T; Zhang, T T; Tang, D D; Liu, S; Li, S; Hu, X W; Mo, Y X; Liu, W Y

Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value

探讨DLL3在胃肠胰神经内分泌肿瘤中的表达及其潜在诊断价值

L Yin # ,R Wang # ,X Ma # ,K Jiang ,Y Hu ,X Zhao ,L Zhang ,Z Wang ,T Long ,M Lu ,J Li ,Y Sun